The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sidorova I.S.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
N.V. Sklifosovskii Institute of Clinical Medicine

Unanyan A.L.

Sechenov First Moscow State Medical University

Nikitina N.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
N.V. Sklifosovskii Institute of Clinical Medicine

Mcdonnell V.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
N.V. Sklifosovskii Institute of Clinical Medicine

Ageev M.B.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
N.V. Sklifosovskii Institute of Clinical Medicine

Modern possibilities of prediction and early diagnosis of preeclampsia

Authors:

Sidorova I.S., Unanyan A.L., Nikitina N.A., Mcdonnell V.A., Ageev M.B.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2021;21(6): 32‑43

DOI: 10.17116/rosakush20212106132

Read: 2406 times

Download PDF (RU)
Contact the author
Table of contents

MODERN POSSIBILITIES OF PREDICTION AND EARLY DIAGNOSIS OF PREECLAMPSIA
MODERN POSSIBILITIES OF PREDICTION AND EARLY DIAGNOSIS OF PREECLAMPSIA

To cite this article:

Sidorova IS, Unanyan AL, Nikitina NA, Mcdonnell VA, Ageev MB. Modern possibilities of prediction and early diagnosis of preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2021;21(6):32‑43. (In Russ.)
https://doi.org/10.17116/rosakush20212106132

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pecu­liarities of placental microRNA expression in patients with preeclampsia and fetal growth restriction. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):14-25
On mole­cular gene­tic predictors of preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):26-34
Prognosis and prevention of recu­rrent and atypical endo­metrial hype­rplasia in women of reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):59-65
Changes in the type of psychological component of the gestational domi­nant in pregnant women in the third trimester after completing the peri­natal preparation program. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):66-71
Sexual function of women during pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):112-117
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
Inflammatory aging. Part 1. The principal biochemical mechanisms. Russian Journal of Preventive Medi­cine. 2024;(12):145-150
Dyna­mics of Substance P and Fila­ggrin Levels on Combined Treatment of Atopic Dermatitis with Emollient and Topi­cal Anti­pruritic Drug in Pregnant Women. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):662-666
Epigenetic regu­lation in the placenta in case of impaired trophoblast inva­sion (a review). Russian Journal of Human Reproduction. 2024;(6):45-54
Functional cyto­kine redu­ndancy in pregnancy. Russian Journal of Human Reproduction. 2024;(6):73-80
Abstract:

The presented literature review reflects modern views of the pathophysiological mechanisms of the development of preeclampsia. An analysis of studies published in the world literature about the most sensitive and specific markers for predicting and early diagnosis of preeclampsia: 25 potential biochemical and 2 biophysical markers in the first and second trimesters of pregnancy is presented. Since the isolated determination of any of the markers described does not satisfy the requirements of practical obstetrics, subsequent research should focus on finding combinations of markers with the necessary predictive accuracy for screening of the prediction and early diagnosis of preeclampsia.

Keywords:

preeclampsia
pregnancy
biomarker
prognosis

Authors:

Sidorova I.S.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
N.V. Sklifosovskii Institute of Clinical Medicine

Unanyan A.L.

Sechenov First Moscow State Medical University

Nikitina N.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
N.V. Sklifosovskii Institute of Clinical Medicine

Mcdonnell V.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
N.V. Sklifosovskii Institute of Clinical Medicine

Ageev M.B.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
N.V. Sklifosovskii Institute of Clinical Medicine

Received:

26.03.2021

Accepted:

23.04.2021

Close metadata

References:

  1. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102:1:181-192.  https://doi.org/10.1016/S0029-7844(03)00475-7
  2. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:5:1122-1131. https://doi.org/10.1097/01.aog.0000437382.03963.88
  3. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014;36:5:416-441.  https://doi.org/10.1016/S1701-2163(15)30588-0
  4. Jhee JH, Lee S, Park Y, Lee SE, Kim YA, Kang SW, Kwon JY, Park JT. Prediction model development of late-onset preeclampsia using machine learning-based methods. PLoS One. 2019;14:8:e0221202. https://doi.org/10.1371/journal.pone.0221202
  5. Leeman L, Fontaine P. Hypertensive disorders of pregnancy. Am Fam Physician. 2008;78:1:93-100. 
  6. Sibai BM. Biomarker for hypertension-preeclampsia: are we close yet? Am J Obstet Gynecol. 2007;197:1:1-2.  https://doi.org/10.1016/j.ajog.2007.04.021
  7. Cedergren MI. Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstet Gynecol. 2004;103:2:219-224.  https://doi.org/10.1097/01.aog.0000107291.46159.00
  8. Cnossen JS, Vollebregt KC, de Vrieze N, ter Riet G, Mol BW, Franx A, Khan KS, van der Post JA. Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis. BMJ. 2008;336:7653:1117-1120. https://doi.org/10.1136/bmj.39540.522049.be
  9. Wright A, Wright D, Ispas CA, Poon LC, Nicolaides KH. Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;45:6:698-706.  https://doi.org/10.1002/uog.14783
  10. Napolitano R, Rajakulasingam R, Memmo A, Bhide A, Thilaganathan B. Uterine artery Doppler screening for pre-eclampsia: comparison of the lower, mean and higher first-trimester pulsatility indices. Ultrasound Obstet Gynecol. 2011;37:5:534-537.  https://doi.org/10.1002/uog.8848
  11. Velauthar L, Plana MN, Kalidindi M, Zamora J, Thilaganathan B, Illanes SE, Khan KS, Aquilina J, Thangaratinam S. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55,974 women. Ultrasound Obstet Gynecol. 2014;43:5:500-507.  https://doi.org/10.1002/uog.13275
  12. Tayyar A, Guerra L, Wright A, Wright D, Nicolaides KH. Uterine artery pulsatility index in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;45:6:689-697.  https://doi.org/10.1002/uog.14789
  13. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008;294:2:541-550.  https://doi.org/10.1152/ajpheart.01113.2007
  14. McMahon K, Karumanchi SA, Stillman IE, Cummings P, Patton D, Easterling T. Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta. Am J Obstet Gynecol. 2014;210:1:68.e1-68.e684. https://doi.org/10.1016/j.ajog.2013.08.032
  15. Saha T, Halder M, Das A, Das SK. Role of nitric oxide, angiogenic growth factors and biochemical analysis in preeclampsia. Indian J Biochem Biophys. 2013;50:5:462-466. 
  16. Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002;196:11:1497-1506. https://doi.org/10.1084/jem.20021244
  17. Vitoratos N, Hassiakos D, Iavazzo C. Molecular mechanisms of preeclampsia. J Pregnancy. 2012;2012:298343. https://doi.org/10.1155/2012/298343
  18. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005;46:5:1077-1085. https://doi.org/10.1161/01.hyp.0000187899.34379.b0
  19. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:5:649-658.  https://doi.org/10.1172/jci17189
  20. Masoura S, Kalogiannidis I, Makedou K, Theodoridis T, Koiou K, Gerou S, Athanasiadis A, Agorastos T. Biomarkers of endothelial dysfunction in preeclampsia and neonatal morbidity: a case-control study. Eur J Obstet Gynecol Reprod Biol. 2014;175:119-123.  https://doi.org/10.1016/j.ejogrb.2014.01.012
  21. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Gonçalves LF, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004;190:6:1541-1550. https://doi.org/10.1016/j.ajog.2004.03.043
  22. Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol. 2005;48:2:372-386.  https://doi.org/10.1097/01.grf.0000160313.82606.d7
  23. Petla LT, Chikkala R, Ratnakar KS, Kodati V, Sritharan V. Biomarkers for the management of pre-eclampsia in pregnant women. Indian J Med Res. 2013;138:1:60-67. 
  24. Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén-Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol. 2007;109:6:1368-1374. https://doi.org/10.1097/01.aog.0000264552.85436.a1
  25. Chen Y. Novel angiogenic factors for predicting preeclampsia: sFlt-1, PlGF, and soluble endoglin. The Open Clinical Chemistry Journal. 2009;2:1:1-6.  https://doi.org/10.2174/1874241600902010001
  26. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim K-H, Yuan H-T, Libermann TA, Stillman IE, Roberts D, D’Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:6:642-649.  https://doi.org/10.1038/nm1429
  27. Levine RJ, Lam C, Qian C, Kai F Yu, Sharon E Maynard, Benjamin P Sachs, Baha M Sibai, Franklin H Epstein, Roberto Romero, Ravi Thadhani, S Ananth Karumanchi, CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:10:992-1005. https://doi.org/10.1056/nejmoa055352
  28. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011;31:1:66-74.  https://doi.org/10.1002/pd.2660
  29. Stepan H, Geipel A, Schwarz F, Krämer T, Wessel N, Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol. 2008;198:2:175.e1-175.e1756. https://doi.org/10.1016/j.ajog.2007.08.052
  30. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:7:672-683.  https://doi.org/10.1056/nejmoa031884
  31. Erez O, Romero R, Maymon E, Chaemsaithong P, Done B, Pacora P, Panaitescu B, Chaiworapongsa T, Hassan SS, Tarca AL. The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. PLoS One. 2017;12:7:e0181468. https://doi.org/10.1371/journal.pone.0181468
  32. Reister F, Kingdom JC, Ruck P, Marzusch K, Heyl W, Pauer U, Kaufmann P, Rath W, Huppertz B. Altered protease expression by periarterial trophoblast cells in severe early-onset preeclampsia with IUGR. J Perinat Med. 2006;34:4:272-279.  https://doi.org/10.1515/jpm.2006.052
  33. Tarca AL, Romero R, Benshalom-Tirosh N, Than NG, Gudicha DW, Done B, Pacora P, Chaiworapongsa T, Panaitescu B, Tirosh D, Gomez-Lopez N, Draghici S, Hassan SS, Erez O. The prediction of early preeclampsia: Results from a longitudinal proteomics study. PLoS One. 2019;14:6:e0217273. https://doi.org/10.1371/journal.pone.0217273
  34. Vettraino IM, Roby J, Tolley T, Parks WC. Collagenase-I, stromelysin-I, and matrilysin are expressed within the placenta during multiple stages of human pregnancy. Placenta. 1996;17:8:557-563.  https://doi.org/10.1016/s0143-4004(96)80072-5
  35. Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, Llurba E, Gratacós E. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenat Diagn. 2015;35:2:183-191.  https://doi.org/10.1002/pd.4519
  36. Tsiakkas A, Cazacu R, Wright A, Wright D, Nicolaides KH. Maternal serum placental growth factor at 12, 22, 32 and 36 weeks’ gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol. 2016;47:4:472-477.  https://doi.org/10.1002/uog.15816
  37. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:7:613-622.  https://doi.org/10.1056/nejmoa1704559
  38. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001;495:3:197-200.  https://doi.org/10.1016/s0014-5793(01)02377-8
  39. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:7:945-952.  https://doi.org/10.1172/jci4106
  40. Xia Y, Ramin SM, Kellems RE. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension. 2007;50:2:269-275.  https://doi.org/10.1161/hypertensionaha.107.091322
  41. Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, Luft FC. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation. 2003;107:12:1632-1639. https://doi.org/10.1161/01.cir.0000058200.90059.b1
  42. LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, Wallukat G, Wenzel K, Cockrell K, Martin JN Jr, Ryan MJ, Dechend R. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension. 2009;54:4:905-909.  https://doi.org/10.1161/hypertensionaha.109.137935
  43. Parrish MR, Murphy SR, Rutland S, Wallace K, Wenzel K, Wallukat G, Keiser S, Ray LF, Dechend R, Martin JN, Granger JP, LaMarca B. The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens. 2010;23:8:911-916.  https://doi.org/10.1038/ajh.2010.70
  44. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:5728:1592-1594. https://doi.org/10.1126/science.1111726
  45. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14:8:855-862.  https://doi.org/10.1038/nm.1856
  46. Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, Cuckle H, Wolf M. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007;197:1:35.e1-35.e357. https://doi.org/10.1016/j.ajog.2007.02.025
  47. Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. Prenat Diagn. 2009;29:8:781-789.  https://doi.org/10.1002/pd.2287
  48. Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther. 2008;24:3:230-236.  https://doi.org/10.1159/000151344
  49. Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, Tal J, Cuckle HS. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol. 2006;27:1:13-17.  https://doi.org/10.1002/uog.2686
  50. Grill S, Rusterholz C, Zanetti-Dällenbach R, Tercanli S, Holzgreve W, Hahn S, Lapaire O. Potential markers of preeclampsia—a review. Reprod Biol Endocrinol. 2009;7:70.  https://doi.org/10.1186/1477-7827-7-70
  51. Staff AC. Circulating predictive biomarkers in preeclampsia. Pregnancy Hypertens. 2011;1:1:28-42.  https://doi.org/10.1016/j.preghy.2010.10.012
  52. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol. 2009;33:1:23-33.  https://doi.org/10.1002/uog.6280
  53. Fasshauer M, Blüher M, Stumvoll M, Tönessen P, Faber R, Stepan H. Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. Clin Endocrinol (Oxf). 2007;66:3:434-439.  https://doi.org/10.1111/j.1365-2265.2007.02751.x
  54. Hu W, Wang Z, Wang H, Huang H, Dong M. Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet Gynecol Scand. 2008;87:4:413-418.  https://doi.org/10.1080/00016340801976012
  55. D’Anna R, Baviera G, Giordano D, Todarello G, Russo S, Recupero S, Bolignano D, Corrado F. Neutrophil gelatinase-associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand. 2010;89:2:275-278.  https://doi.org/10.3109/00016340903443676
  56. Canzoneri BJ, Lewis DF, Groome L, Wang Y. Increased neutrophil numbers account for leukocytosis in women with preeclampsia. Am J Perinatol. 2009;26:10:729-732.  https://doi.org/10.1055/s-0029-1223285
  57. Karampas GA, Eleftheriades MI, Panoulis KC, Rizou MD, Haliassos AD, Metallinou DK, Mastorakos GP, Rizos DA. Prediction of pre-eclampsia combining NGAL and other biochemical markers with Doppler in the first and/or second trimester of pregnancy. A pilot study. Eur J Obstet Gynecol Reprod Biol. 2016;205:153-157.  https://doi.org/10.1016/j.ejogrb.2016.08.034
  58. Saxena AR, Ananth Karumanchi S, Fan SL, Horowitz GL, Hollenberg NK, Graves SW, Seely EW. Correlation of cystatin-C with glomerular filtration rate by inulin clearance in pregnancy. Hypertens Pregnancy. 2012;31:1:22-30.  https://doi.org/10.3109/10641955.2010.507845
  59. Kristensen K, Larsson I, Hansson SR. Increased cystatin C expression in the pre-eclamptic placenta. Mol Hum Reprod. 2007;13:3:189-195.  https://doi.org/10.1093/molehr/gal111
  60. Thilaganathan B, Ralph E, Papageorghiou AT, Melchiorre K, Sheldon J. Raised maternal serum cystatin C: an early pregnancy marker for preeclampsia. Reprod Sci. 2009;16:8:788-793.  https://doi.org/10.1177/1933719109336618
  61. Risch M, Purde MT, Baumann M, Mohaupt M, Mosimann B, Renz H, Raio L, Surbek D, Risch L. High first-trimester maternal blood cystatin C levels despite normal serum creatinine predict pre-eclampsia in singleton pregnancies. Scand J Clin Lab Invest. 2017;77:8:634-643.  https://doi.org/10.1080/00365513.2017.1393692
  62. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:10:4068-4071.
  63. Frölich MA, Datta S, Corn SB. Thrombopoietin in normal pregnancy and preeclampsia. Am J Obstet Gynecol. 1998;179:1:100-104.  https://doi.org/10.1016/s0002-9378(98)70257-1
  64. Carroll RC, Owers RL, Elder RF, Hennessey MD, Patteson SK, Snider CC, Muenchen RA. Lack of thrombopoietin potentiation of platelet collagen activation in the first trimester is associated with preeclampsia. Thromb Res. 2005;116:1:51-54.  https://doi.org/10.1016/j.thromres.2004.11.007
  65. Johnson J, Kniss D, Samuels P. Thrombopoietin in pre-eclampsia and HELLP syndrome. Am J Obstet Gynecol. 2001;185:6:S83.  https://doi.org/10.1016/s0002-9378(01)80068-5
  66. Uszyński M, Uszyński W, Zekanowska E. P-selectin in placenta and gestational myometrium: its measurements and hypothetical role in hemostasis of placental bed after labor. J Perinat Med. 2008;36:3:213-216.  https://doi.org/10.1515/jpm.2008.037
  67. Wasiluk A. Markers of platelets activation, CD 62P and soluble P-selectin in healthy term neonates. J Perinat Med. 2004;32:6:514-515.  https://doi.org/10.1515/jpm.2004.123
  68. Burrows TD, King A, Loke YW. Expression of adhesion molecules by endovascular trophoblast and decidual endothelial cells: implications for vascular invasion during implantation. Placenta. 1994;15:1:21-33.  https://doi.org/10.1016/s0143-4004(05)80233-4
  69. Holthe MR, Staff AC, Berge LN, Lyberg T. Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women. Am J Obstet Gynecol. 2004;190:4:1128-1134. https://doi.org/10.1016/j.ajog.2003.10.699
  70. Bosio PM, Cannon S, McKenna PJ, O’Herlihy C, Conroy R, Brady H. Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia. BJOG. 2001;108:7:709-715.  https://doi.org/10.1111/j.1471-0528.2001.00170.x
  71. Laskowska M, Laskowska K, Oleszczuk J. Elevated maternal serum sP-selectin levels in preeclamptic pregnancies with and without intrauterine fetal growth restriction, but not in normotensive pregnancies complicated by isolated IUGR. Med Sci Monit. 2013;19:118-124.  https://doi.org/10.12659/msm.883780
  72. Köninger A, Enekwe A, Mach P, Andrikos D, Schmidt B, Frank M, Birdir C, Kimmig R, Gellhaus A, Dieplinger H. Afamin: an early predictor of preeclampsia. Arch Gynecol Obstet. 2018;298:5:1009-1016. https://doi.org/10.1007/s00404-018-4897-z
  73. Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension. 2008;52:5:873-880.  https://doi.org/10.1161/hypertensionaha.108.117358
  74. Hubalek M, Buchner H, Mörtl MG, Schlembach D, Huppertz B, Firulovic B, Köhler W, Hafner E, Dieplinger B, Wildt L, Dieplinger H. The vitamin E-binding protein afamin increases in maternal serum during pregnancy. Clin Chim Acta. 2014;434:100:41-47.  https://doi.org/10.1016/j.cca.2014.03.036
  75. Holden DP, Fickling SA, Whitley GS, Nussey SS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol. 1998;178:3:551-556.  https://doi.org/10.1016/s0002-9378(98)70437-5
  76. Braekke K, Ueland PM, Harsem NK, Staff AC. Asymmetric dimethylarginine in the maternal and fetal circulation in preeclampsia. Pediatr Res. 2009;66:4:411-415.  https://doi.org/10.1203/pdr.0b013e3181b33392
  77. Savvidou MD, Hingorani AD, Tsikas D, Frölich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003;361:9368:1511-1517. https://doi.org/10.1016/s0140-6736(03)13177-7
  78. Bahtiyar MO, Buhimschi C, Ravishankar V, Copel J, Norwitz E, Julien S, Guller S, Buhimschi IA. Contrasting effects of chronic hypoxia and nitric oxide synthase inhibition on circulating angiogenic factors in a rat model of growth restriction. Am J Obstet Gynecol. 2007;196:1:72.e1-72.e726. https://doi.org/10.1016/j.ajog.2006.07.048
  79. Marzioni D, Quaranta A, Lorenzi T, Morroni M, Crescimanno C, De Nictolis M, Toti P, Muzzonigro G, Baldi A, De Luca A, Castellucci M. Expression pattern alterations of the serine protease HtrA1 in normal human placental tissues and in gestational trophoblastic diseases. Histol Histopathol. 2009;24:10:1213-1222. https://doi.org/10.14670/hh-24.1213
  80. Gesuita R, Licini C, Picchiassi E, Tarquini F, Coata G, Fantone S, Tossetta G, Ciavattini A, Castellucci M, Di Renzo GC, Giannubilo SR, Marzioni D. Association between first trimester plasma htra1 level and subsequent preeclampsia: A possible early marker? Pregnancy Hypertens. 2019;18:58-62.  https://doi.org/10.1016/j.preghy.2019.08.005
  81. Marzioni D, Lorenzi T, Altobelli E, Giannubilo SR, Paolinelli F, Tersigni C, Crescimanno C, Monsurrò V, Tranquilli AL, Di Simone N, Castellucci M. Alterations of maternal plasma HTRA1 level in preeclampsia complicated by IUGR. Placenta. 2012;33:12:1036-1038. https://doi.org/10.1016/j.placenta.2012.09.011
  82. Centlow M, Carninci P, Nemeth K, Mezey E, Brownstein M, Hansson SR. Placental expression profiling in preeclampsia: local overproduction of hemoglobin may drive pathological changes. Fertil Steril. 2008;90:5:1834-1843. https://doi.org/10.1016/j.fertnstert.2007.09.030
  83. Anderson UD, Gram M, Ranstam J, Thilaganathan B, Kerström B, Hansson SR. Fetal hemoglobin, α1-microglobulin and hemopexin are potential predictive first trimester biomarkers for preeclampsia. Pregnancy Hypertens. 2016;6:2:103-109.  https://doi.org/10.1016/j.preghy.2016.02.003
  84. Hansson SR, Nääv Å, Erlandsson L. Oxidative stress in preeclampsia and the role of free fetal hemoglobin. Front Physiol. 2015;5:516.  https://doi.org/10.3389/fphys.2014.00516
  85. Petraglia F, Potter E, Cameron VA, Sutton S, Behan DP, Woods RJ, Sawchenko PE, Lowry PJ, Vale W. Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues. J Clin Endocrinol Metab. 1993;77:4:919-924.  https://doi.org/10.1210/jcem.77.4.8408466
  86. Woods RJ, Grossman A, Saphier P, Kennedy K, Ur E, Behan D, Potter E, Vale W, Lowry PJ. Association of human corticotropin-releasing hormone to its binding protein in blood may trigger clearance of the complex. J Clin Endocrinol Metab. 1994;78:1:73-76.  https://doi.org/10.1210/jcem.78.1.8288718
  87. Florio P, Imperatore A, Sanseverino F, Torricelli M, Reis FM, Lowry PJ, Petraglia F. The measurement of maternal plasma corticotropin-releasing factor (CRF) and CRF-binding protein improves the early prediction of preeclampsia. J Clin Endocrinol Metab. 2004;89:9:4673-4677. https://doi.org/10.1210/jc.2004-0186
  88. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet. 1997;349:9061:1285-1288. https://doi.org/10.1016/s0140-6736(96)09264-1
  89. Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J, Ledger W, Groome N, Redman CW. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod. 2000;15:7:1640-1645. https://doi.org/10.1093/humrep/15.7.1640
  90. Florio P, Reis FM, Pezzani I, Luisi S, Severi FM, Petraglia F. The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2003;21:2:165-169.  https://doi.org/10.1002/uog.29
  91. Forbes K, Westwood M. The IGF axis and placental function. a mini review. Horm Res. 2008;69:3:129-137.  https://doi.org/10.1159/000112585
  92. Vatten LJ, Nilsen TI, Juul A, Jeansson S, Jenum PA, Eskild A. Changes in circulating level of IGF-I and IGF-binding protein-1 from the first to second trimester as predictors of preeclampsia. Eur J Endocrinol. 2008;158:1:101-105.  https://doi.org/10.1530/eje-07-0386
  93. Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH. Maternal serum insulin-like growth factor-I at 11-13 weeks in preeclampsia. Prenat Diagn. 2010;30:11:1026-1031. https://doi.org/10.1002/pd.2555
  94. Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH. Maternal serum insulin-like growth factor-binding protein-1 (IGFBP-1) at 11-13 weeks in pre-eclampsia. Prenat Diagn. 2011;31:2:196-201.  https://doi.org/10.1002/pd.2682
  95. Hendler I, Blackwell SC, Mehta SH, Whitty JE, Russell E, Sorokin Y, Cotton DB. The levels of leptin, adiponectin, and resistin in normal weight, overweight, and obese pregnant women with and without preeclampsia. Am J Obstet Gynecol. 2005;193(3 Pt 2):979-983.  https://doi.org/10.1016/j.ajog.2005.06.041
  96. Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, Akahori Y, Hiramatsu Y. Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG. 2010;117:3:314-320.  https://doi.org/10.1111/j.1471-0528.2009.02453.x
  97. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:9741:631-644.  https://doi.org/10.1016/s0140-6736(10)60279-6
  98. Kajantie E, Kaaja R, Ylikorkala O, Andersson S, Laivuori H. Adiponectin concentrations in maternal serum: elevated in preeclampsia but unrelated to insulin sensitivity. J Soc Gynecol Investig. 2005;12:6:433-439.  https://doi.org/10.1016/j.jsgi.2005.04.006
  99. Ramsay JE, Jamieson N, Greer IA, Sattar N. Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension. 2003;42:5:891-894.  https://doi.org/10.1161/01.hyp.0000095981.92542.f6
  100. Cortelazzi D, Corbetta S, Ronzoni S, Pelle F, Marconi A, Cozzi V, Cetin I, Cortelazzi R, Beck-Peccoz P, Spada A. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. Clin Endocrinol (Oxf). 2007;66:3:447-453.  https://doi.org/10.1111/j.1365-2265.2007.02761.x
  101. D’Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nicocia G, Di Benedetto A. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. BJOG. 2006;113:11:1264-1269. https://doi.org/10.1111/j.1471-0528.2006.01078.x
  102. Salimi S, Farajian-Mashhadi F, Naghavi A, Mokhtari M, Shahrakipour M, Saravani M, Yaghmaei M. Different profile of serum leptin between early onset and late onset preeclampsia. Dis Markers. 2014;2014:628476. https://doi.org/10.1155/2014/628476
  103. Ning Y, Williams MA, Muy-Rivera M, Leisenring WM, Luthy DA. Relationship of maternal plasma leptin and risk of pre-eclampsia: a prospective study. J Matern Fetal Neonatal Med. 2004;15:3:186-192.  https://doi.org/10.1080/14767050410001668293
  104. Liu Y, Zhu L, Pan Y, Sun L, Chen D, Li X. Adiponectin levels in circulation and breast milk and mRNA expression in adipose tissue of preeclampsia women. Hypertens Pregnancy. 2012;31:1:40-49.  https://doi.org/10.3109/10641955.2010.525273
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.